Zobrazeno 41 - 50
of 4 806
pro vyhledávání: ''
Autor:
Yalei Chen, Benjamin A. Rybicki, Kevin R. Bobbitt, K Arora, Watchareepohn Palangmonthip, Dhananjay Chitale, Sudha M. Sadasivan, Deliang Tang, Nilesh S. Gupta, Andrew Rundle, Oleksandr Kravtsov, Sean R Williamson, Kenneth A. Iczkowski
Publikováno v:
Cancer Medicine, Vol 10, Iss 9, Pp 3013-3025 (2021)
Cancer Medicine
Cancer Medicine
Growth and differentiation factor 15 (GDF‐15), also known as macrophage inhibitory cytokine 1 (MIC‐1), may act as both a tumor suppressor and promotor and, by regulating NF‐κB and macrophage signaling, promote early prostate carcinogenesis. To
Autor:
Audrey J. Lazenby, Chandrakanth Are, Lynette M. Smith, Michael G. Brattain, Premila D. Leiphrakpam
Publikováno v:
Journal of Surgical Oncology. 123:1764-1772
OBJECTIVES To evaluate the relationship between stathmin expression and clinical outcome in colorectal cancer (CRC). BACKGROUND Stathmin is a phosphoprotein involved in the regulation of microtubule dynamics and integration of intracellular signaling
Autor:
Yoshihiko Murata, Tomoki Nakagawa, Yunjung Kim, Junko Kano, Masayuki Noguchi, Zeinab Kosibaty, Noriaki Sakamoto
Publikováno v:
Pathology International
The expression of Ras-specific guanine nucleotide-releasing factor 2 (RasGRF2) in lung adenocarcinomas was examined using immunohistochemistry in relation to clinicopathological characteristics and prognosis. In comparison to low expression, high exp
Autor:
Zenan Lin, Daniela Süsskind
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 147:1389-1405
While B-cell activating factor (BAFF) was identified to promote the invasion in other malignancies, its role in the progression of uveal melanoma (UM) still remains unexplored. Here, we analysed the serum level of BAFF in UM patients with regard to i
Autor:
Nobuhide Higashino, Mari Nishio, Masaki Shimizu, Yoshihiro Kakeji, Masataka Fujikawa, Takayuki Kodama, Hiroki Sakamoto, Hiroshi Yokozaki, Kohei Tanigawa, Manabu Shigeoka, Yu-ichiro Koma
Publikováno v:
Laboratory Investigation; a Journal of Technical Methods and Pathology
Cancer-associated fibroblasts (CAFs) contribute to the progression of various cancers. Previously, we reported the significance of CAFs in esophageal squamous cell carcinoma (ESCC); however, the functions of CAFs in the ESCC microenvironment remain u
Autor:
Bin Zhao, Yang Zhai, Lina Li, Jingjin Li, Linhan Chang, Zijun Liao, Yuzhen Wang, Qian Chen, Xu Li
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Cancer
BMC Cancer
Background Lung adenocarcinoma (LUAD) is the most common pathology subtype of lung cancer. In recent years, immunotherapy, targeted therapy and chemotherapeutics conferred a certain curative effects. However, the effect and prognosis of LUAD patients
Autor:
Mitsugu Sekimoto, Tomoharu Sugie, Hirotsugu Yanai, Katsuhiro Yoshikawa, Koji Tsuta, Mitsuaki Ishida
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer
BMC Cancer
Background Cancer-associated fibroblasts (CAFs) are some of the most abundant components of the tumour microenvironment. A recent study suggested that in some cancers, CAFs express programmed death ligand 1 (PD-L1), which can act as a prognostic mark
Autor:
Giovanni Scambia, Panos Z. Anastasiadis, Gary L. Keeney, Gian Franco Zannoni, Giorgia Dinoi, Daniela Gallo, Amy L. Weaver, Francesco Fanfani, Andrea Mariani, Enrica Martinelli, Alessandra Ciucci, George Vasmatzis
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Objective Serous endometrial cancer (USC) is a challenging malignancy associated with metastasis, recurrence and poor outcome. To identify clinically relevant prognostic biomarkers, we focused on a panel of proteins selected after a comprehensive lit
Autor:
Soo-Ryum Yang, Achim A. Jungbluth, Ezra Y. Rosen, Douglas A. Mata, Kerry Mullaney, Umut Aypar, Denise Frosina, Alexander Drilon, Marc Ladanyi, Jaclyn F. Hechtman, Yanming Zhang, Gowtham Jayakumaran, Natasha Rekhtman, Ryma Benayed
Publikováno v:
Clin Cancer Res
Purpose: Selpercatinib and pralsetinib induce deep and durable responses in patients with advanced RET fusion–positive lung and thyroid cancer. RET fusion testing strategies with rapid and reliable results are critical given recent FDA approval. He
Autor:
Takafumi Morisaki, Karen Zaguirre, Masaya Kai, Hitomi Kawaji, Hitomi Mori, Makoto Kubo, Shuji Shimizu, Sanmei Chen, Mai Yamada, Kanako Kurata, Masafumi Nakamura, Akiko Shimazaki, Yoshinao Oda, Taiki Moriyama, Yurina Harada, Saori Hayashi, Kazuhisa Kaneshiro
Publikováno v:
Cancer Medicine, Vol 10, Iss 5, Pp 1605-1613 (2021)
Cancer Medicine
Cancer Medicine
Introduction PREDICT is a prognostication tool that calculates the potential benefit of various postsurgical treatments on the overall survival (OS) of patients with nonmetastatic invasive breast cancer. Once patient, tumor, and treatment details hav